Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 11, 2005, Pages 4515-4520

  Mishin, Vasiliy P ^a,c   Hayden, Frederick G ^a   Gubareva, Larisa V ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; A 315675; A 322278; AMANTADINE; ASPARAGINE; ASPARTIC ACID; OSELTAMIVIR; PERAMIVIR; PLACEBO; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; FERRET; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIROGENESIS; VIRUS SHEDDING;

ANIMALS; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; FERRETS; INFLUENZA, HUMAN; MUTATION; NEURAMINIDASE; ORTHOMYXOVIRIDAE;

EID: 27644439501     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.11.4515-4520.2005     Document Type: Article

References (41)

1. Abed, Y., N. Goyette, and G. Boivin. 2004. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antiviral Ther. 9:577-581.
2. Babu, Y. S., P. Chand, S. Bantia, P. Kotian, A. Dehghani, Y. El Kattan, T. H. Lin, T. L. Hutchison, A. J. Elliott, C. D. Parker, S. L. Ananth, L. L. Horn, G. W. Laver, and J. A. Montgomery. 2000. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43:3482-3486.
3. Burmeister, W. P., R. W. Ruigrok, and S. Cusack. 1992. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11:49-56.
4. Carr, J., J. Ives, L. Kelly, R. Lambkin, J. Oxford, D. Mendel, L. Tai, and N. Roberts. 2002. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and rcplicative ability in vivo. Antiviral Res. 54:79-88.
5. Cheam, A. L., I. G. Barr, A. W. Hampson, J. Mosse, and A. C. Hurt. 2004. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antiviral Res. 63:177-181.
6. Colacino, J. M. 1996. Resistance of influenza A and B viruses to 4-guanidino-Neu5Ac2en, p. 741-747. In L. E. Brown, A. W. Hampson, and R. G. Webster (ed.), Options for the control of influenza. Elsevier, Amsterdam, The Netherlands.
7. Colman, P. M. 1989. Neuraminidase: enzyme and antigen, p. 175-210. In R. M. Krug (ed.), The influenza viruses. Plenum Press, New York, N.Y.
8. Covington, E., D. B. Mendel, P. A. Escarpe, C. Y. Tai, K. Soberbarg, and N. A. Roberts. 2000. Phenotypic and genotypic assay of influenza virus neuraminidase indicates a low incidence of viral drug resistance during treatment with oseltamivir. J. Clin. Virol. 18:P326.
9. Fouchier, R. A., V. Munster, A. Wallensten, T. M. Bestebroer, S. Herfst, D. Smith, G. F. Rimmelzwaan, B. Olsen, and A. D. Osterhaus. 2005. Characterization of a novel influenza a virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79:2814-2822.
10. Govorkova, E. A., I. A. Leneva, O. G. Goloubeva, and K. Bush. 2001. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45:2723-2732.
11. Gubareva, L. V. 2004. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 103:199-203.
12. Gubareva, L. V., R. Bethell, G. J. Hart, K. G. Murti, C. R. Penn, and R. G. Webster. 1996. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 70:1818-1827.
13. Gubareva, L. V., L. Kaiser, and F. G. Hayden. 2000. Influenza virus neuraminidase inhibitors. Lancet 355:827-835.
14. Gubareva, L. V., L. Kaiser, M. N. Matrosovich, Y. Soo-Hoo, and F. G. Hayden. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523-531.
15. Gubareva, L. V., M. N. Matrosovich, M. K. Brenner, R. C. Bethell, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
16. Gubareva, L. V., M. J. Robinson, R. C. Bethell, and R. G. Webster. 1997. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71:3385-3390.
17. Gubareva, L. V., R. G. Webster, and F. G. Hayden. 2002. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53:47-61.
18. Hayden, F. G. 1996. Amantadine and rimantadine-clinical aspects, p. 59-77. In D. D. Richman (ed.), Antiviral drug resistance. John Wiley & Sons Ltd., New York, N.Y.
19. Hayden, F. G., J. J. Treanor, R. S. Fritz, M. Lobo, R. F. Betts, M. Miller, Kinnersley, N., R. G. Mills, P. Ward, and S. E. Straus. 1999. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282:1240-1246.
20. Herlocher, M. L., J. Carr, J. Ives, S. Elias, R. Truscon, N. Roberts, and A. S. Monto. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:99-111.
21. Herlocher, M. L., R. Truscon, S. Elias, H. L. Yen, N. A. Roberts, S. E. Ohmit, and A. S. Monto. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630.
22. Hurt, A. C., J. L. McKimm-Breschkin, M. Mcdonald, I. G. Barr, N. Komadina, and A. W. Hampson. 2004. Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Res. 103:205-211.
23. Jackson, D., W. Barclay, and T. Zurcher. 2005. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J. Antimicrob. Chemother. 55:162-169.
24. Jackson, H. C., N. Roberts, Z. M. Wang, and R. Belshe. 2000. Management of influenza. Use of new antivirals and resistance in perspective. Clin. Drug Investig. 20:447-454.
25. Kati, W. M., D. Montgomery, R. Carrick, L. Gubareva, C. Maring, K. McDaniel, K. Steffy, A. Molla, F. Hayden, D. Kempf, and W. Kohlbrenner. 2002. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother. 46:1014-1021.
26. Kim, C. U., W. Lew, M. A. Williams, H. Wu, L. Zhang, X. Chen, P. A. Escarpe, D. B. Mendel, W. G. Laver, and R. C. Stevens. 1998. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem. 41:2451-2460.
27. Kiso, M., K. Mitamura, Y. Sakai-Tagawa, K. Shiraishi, C. Kawakami, K. Kimura, F. G. Hayden, N. Sugaya, and Y. Kawaoka. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765.
28. Li, K. S., Y. Guan, J. Wang, G. J. Smith, K. M. Xu, L. Duan, A. P. Rahardjo, P. Puthavathana, C. Buranathai, T. D. Nguyen, A. T. Estoepangestie, A. Chaisingh, P. Auewarakul, H. T. Long, N. T. Hanh, R. J. Webby, L. L. Poon, H. Chen, K. F. Shortridge, K. Y. Yuen, R. G. Webster, and J. S. Peiris. 2004. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430:209-213.
29. McKimm-Breschkin, J., T. Trivedi, A. Hampson, A. Hay, A. Klimov, M. Tashiro, F. Hayden, and M. Zambon. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47:2264-2272.
30. McKimm-Breschkin, J. L. 2000. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res. 47:1-17.
31. Mendel, D. B., C. Y. Tai, P. A. Escarpe, W. Li, R. W. Sidwell, J. H. Huffman, C. Sweet, K. J. Jakeman, J. Merson, S. A. Lacy, W. Lew, M. A. Williams, L. Zhang, M. S. Chen, N. Bischofberger, and C. U. Kim. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42:640-646.
32. Molla, A., W. Kati, R. Carrick, K. Steffy, Y. Shi, D. Montgomery, N. Gusick, V. S. Stoll, K. D. Stewart, T. I. Ng, C. Maring, D. J. Kempf, and W. Kohlbrenner. 2002. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J. Virol. 76:5380-5386.
33. Potier, M., L. Mameli, M. Belisle, L. Dallaire, and S. B. Melancon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha- D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
34. Roberts, N. A. 2001. Treatment of influenza with neuraminidase inhibitors: virological implications. Phil. Trans. R. Soc. Lond. B Biol. Sci. 356:1895-1897.
35. Sweet, C., K. J. Jakeman, K. Bush, P. C. Wagaman, L. A. McKown, A. J. Streeter, D. Desai-Krieger, P. Chand, and Y. S. Babu. 2002. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob. Agents Chemother. 46:996-1004.
36. Trampuz, A., R. M. Prabhu, T. F. Smith, and L. M. Baddour. 2004. Avian influenza: a new pandemic threat? Mayo Clin. Proc. 79:523-530.
37. von Itzstein, M., W. Y. Wu, G. B. Kok, M. S. Pegg, J. C. Dyason, B. Jin, T. Van Phan, M. L. Smythe, H. F. White, and S. W. Oliver. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
38. Webster, R. G. 1997. Predictions for future human influenza pandemics. J. Infect. Dis. 176(Suppl. 1):S14-S19.
39. Weinstock, D. M., L. V. Gubareva, and G. Zuccotti. 2003. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N. Engl. J. Med. 348:867-868.
40. Whitley, R. J., F. G. Hayden, K. S. Reisinger, N. Young, R. Dutkowski, D. Ipe, R. G. Mills, and P. Ward. 2001. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20:127-133.
41. Wright, P. F., and R. G. Webster. 2001. Orthomyxoviruses, p. 1533-1579. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, Pa.